Scientific, Regulatory & Strategic Consulting Services For The Life Sciences Industry
We provide scientific evaluation and business case analysis for potential assets in multiple therapeutic areas including metabolic disease, cardiovascular, GI, respiratory, WH/reproductive health, oncology, inflammation/autoimmunity and immuno-oncology/IO
At BioPoint Consulting, LLC, we help clients build contract work with CROs and academic units focused on drug development. We also help design preclinical studies, clinical development plans and review project proposals
Services include project and vendor management, medical writing support and regulatory strategy
What's Your Story? Let BioPoint Help You Tell It
Our Services
Business Asset Evaluation
Scientific evaluation of business assets for in-licensing activities, evaluation and analysis of data sets, due diligence and business intelligence builds. Services include growth market analysis and pitch deck presentations
Drug Discovery/Preclinical Development
Evaluation and recommendation of in vitro and in vivo animal models of human disease, pharmacology, toxicology, PK/PD, study design and protocol builds, target identification and report summaries. Services include slide presentations plus conference poster synthesis
Medical Writing/Regulatory Strategy
Report generation, IND and IB synthesis, NDA/BLA builds, preIND summaries, regulatory responses, FDA, EMA, PDMA. Strategy for biologics, small molecule, cellular therapeutics. 505b1, 505b2, 505j
Client reviews
"I had the pleasure of working with Matthew via his BioPoint Consulting service the past seven months. Matthew provided excellent scientific advice on quite a few due diligence assets in the cardiovascular/metabolism and immuno-oncology area. Matthew provided prompt reviews and detailed summary for all the projects sometimes with a turn around time of less than 24 hours. His interactions with external colleagues and collaborators was very professional and I always got a very positive response about his subject area expertise from my colleagues. Matthew, through his extensive network community provided excellent choices for conducting research based studies at CROs."